REGN stock forecast: what analysts expect
Wall Street analysts covering Regeneron Pharmaceuticals, Inc. currently rate the stock a Buy on average, with a mean 12-month price target of $833.54 — +4.5% versus the last price of $797.99. Targets reflect analyst opinion, not a guarantee.
REGN historical returns
Based on monthly dividend-adjusted prices. See the full breakdown on what if you had invested in REGN.
REGN annual returns by year
Congress trading in REGN
14 members of Congress have disclosed trading REGN — 13 purchases and 16 sales worth an estimated $354,502. Most recent disclosure: May 15, 2026.
See who in Congress traded REGN →Insider activity in REGN
REGN's own executives and directors have made 0 open-market purchases ($0) and 3 sales ($1.1M) in the last 90 days, per SEC Form 4 filings. Most recent: Aug 10, 2026.
| Aug 10, 2026 | Guarini Kathryn | Director | Sell | $320,000 |
| Aug 10, 2026 | Zoghbi Huda Y | Director | Sell | $640,000 |
| Jul 2, 2026 | Ryan Arthur F | Director | Sell | $130,030 |
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.
REGN Key Statistics
REGN in plain English
- P/E ratio (19.7) — how many dollars you pay for each $1 of REGN's yearly profit. That's a fairly normal range.
- ROE (14.04%) — how efficiently the company turns shareholders' money into profit. This is a middling level.
- Profit margin (27.87%) — of every $1 in sales, this is what's left as profit after all costs.
- Dividend yield (0.47%) — the cash payout you'd earn per year as a % of the share price, on top of any price gains.
REGN stock: frequently asked questions
What is Regeneron Pharmaceuticals, Inc.'s stock price today?
Regeneron Pharmaceuticals, Inc. (REGN) last traded at $797.99 on the NASDAQ. Over the past 52 weeks the stock has traded between $541.00 and $821.11.
Is REGN stock a buy or a sell?
Wall Street analysts' consensus rating on REGN is "Buy", with an average 12-month price target of $833.54 — about +4.5% versus the current price of $797.99. Analyst targets are opinions, not guarantees; always do your own research.
How much would $1,000 invested in REGN 10 years ago be worth today?
A $1,000 investment in Regeneron Pharmaceuticals, Inc. made 10 years ago would be worth about $2,050 today (dividends reinvested) — a total return of 105%, or 7.4% per year.
Does REGN pay a dividend?
Yes. Regeneron Pharmaceuticals, Inc. currently pays a dividend yielding about 0.47% per year at today's share price.
What is REGN's P/E ratio?
REGN trades at a trailing price-to-earnings ratio of 19.7, and 13.3 times expected forward earnings. The P/E ratio tells you how many dollars investors pay for each $1 of the company's annual profit.
Do members of Congress trade REGN stock?
Yes — 14 members of Congress have disclosed trades in REGN under the STOCK Act, totaling 13 purchases and 16 sales worth an estimated $354,502.
What is Regeneron Pharmaceuticals, Inc.'s ticker symbol?
Regeneron Pharmaceuticals, Inc. trades under the ticker symbol REGN on the NASDAQ.
Compare REGN with peers
Data last refreshed from public sources. Figures may be delayed. Not investment advice.